My PCR Releases New Resource on Treatment Free Remission (TFR)

My PCR Releases New Resource on Treatment Free Remission (TFR)

My PCR has released a new FAQ about Treatment Free Remission (TFR) – a potential treatment goal for some patients living with chronic myeloid leukemia (CML).

To keep patients at the center of our process, the Max team asked patient leaders and associations from around the world to send in their own questions about TFR. We compiled their submissions, identified common themes, and narrowed the field down to 10 key questions.

Download the My PCR Treatment-Free Remission FAQ (PDF)

The answers in the FAQ were provided by CML expert, Max Medical Advisor, and friend of the organization, Dr. Michael J. Mauro of Memorial Sloan Kettering Cancer Center. Thanks to his extensive knowledge and experience, the document offers valuable information for patients and providers alike.

This FAQ marks another new resource created by The Max Foundation’s My PCR initiative – a global effort to increase access to polymerase chain reaction (PCR) testing for CML.

The Max Foundation extends its thanks to all the generous sponsors who make the My PCR initiative possible:

  • Major Sponors: Bristol-Myers Squibb, Pfizer, Novartis, and Takeda Oncology
  • Supporting Sponsors: Asuragen, Cepheid, and Incyte

With their support we’re expanding access to critical diagnostics in low- and middle-income countries around the world.

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation expands collaboration with Pfizer

    The Max Foundation expands collaboration with Pfizer

    The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.

  • Join us at the American Society of Hematology (ASH)

    Join us at the American Society of Hematology (ASH)

    Traveling to the American Society of Hematology’s (ASH) annual meeting on December 7–10? We hope to see you at one of our sessions! Save these events to your calendar: The Max Foundation and iCMLf: Forum for Physicians from Emerging Economic Regions When & Where: Friday, December 6, from 12–2 p.m. at the Rosen Plaza Hotel in Orlando, Florida. Each year, ASH joins thousands of leaders around the world….

  • Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board

    Welcoming Dr. Michael J. Wagner, MD, to The Max Foundation’s Medical Advisory Board

    The Max Foundation is thrilled to welcome Dr. Michael J. Wagner to our Gastrointestinal Stromal Tumor (GIST) Medical Advisory Board. Since we met Dr. Wagner in early 2020 at a GIST patient meeting in Seattle, he has provided our program with invaluable training and support. “Dr. Wagner has gone above and beyond in advising our….